

PRESS RELEASE – June 2017

ProteoFormiX and Clarity Genomics join the JLINX Community

JLINX was launched in April 2016 by Janssen Pharmaceutica in collaboration with Bioqube Ventures. This new investment and incubation model provides young entrepreneurs with a unique combination of resources: venture capital, expertise, infrastructure and capabilities. JLINX is located on the Janssen Campus in Beerse, Belgium and is managed by Bioqube Ventures.

JLINX is proud to welcome two new companies to the Community: ProteoFormiX and Clarity Genomics.

ProteoFormiX - New Technologies for Detecting Disease

ProteoFormiX is developing a mass spectrometry-based technology platform to identify disease associated peptides in bodily tissue and fluid. Mass spectrometry diagnostics hold significant potential for the rapid and accurate diagnosis of multiple disorders simultaneously in a single small-volume sample. Prof. Peter Verhaert, Founder and CEO of ProteoFormiX explains: “After having heard about JLINX, and after a few brainstorm sessions with the Bioqube Ventures team, it dawned to me that the best way to have my dreams realized, might actually be starting my own company – and a couple of months later ProteoFormiX was born”.

Clarity Genomics - Analyzing the Host-Microbiome Relationship

We have a growing understanding of the important role that the microbiome plays in human health, but how exactly the microbiome exerts its influence still remains a mystery. Clarity Genomics is developing a platform that learns how human microbiome communities interact with the host through analysis of genetic, functional, and metabolic data and applies this knowledge to facilitate biomarker discovery and patient stratification for better healthcare. Jenya Kopylova, Founder and Principal Research Scientist of Clarity Genomics explains why she joined the JLINX community: “The value of being at JLINX, among ‘peers’ going through the same process of establishing a small biotech start-up, is priceless. No doubt that without the encouraging support by Bioqube Ventures and Janssen experts, I would not be in the position where I am today.”

For more information about JLINX, go to <https://www.jlinnovation.com/jlinx>